Seamless Therapeutics is a TU Dresden spin-out that has created a proprietary genome-editing platform capable of repairing genetic ‘misspellings’ at their source, offering the possibility of curative treatments for disorders such as inherited hearing loss. The technology grew out of research in the university’s Medical Faculty and is protected by patents supported through TUD|excite and the SaxoCell cluster. By enabling highly precise gene corrections rather than symptomatic treatment, the company positions itself at the forefront of next-generation gene therapies. The startup benefits from one of Germany’s strongest academic patent portfolios and Dresden’s growing life-science ecosystem. Its immediate focus is to advance the platform into clinical applications, leveraging strategic industry partnerships to accelerate development. Financially, Seamless Therapeutics’ most significant backing now comes from a multi-billion collaboration agreement with Eli Lilly, underscoring strong commercial validation of its science.

Total raised

$13M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2023